Roche Licenses Sefaxersen from Ionis Pharmaceuticals
Roche has entered into a licensing agreement with Ionis Pharmaceuticals to acquire the rights to sefaxersen for the treatment of complement-mediated diseases.
Stocks · News reference
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Roche announced positive interim phase III data from the IMAgINATION study showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with primary IgA nephropathy. The antisense oligonucleotide inhibitor of complement factor B was well tolerated with no new safety signals and is designed as a once-monthly subcutaneous injection for self-administration.
8-K filing — IONIS PHARMACEUTICALS INC (IONS)
Filed: 2026-10-23 AccNo: 0001140361-26-040631 Size: 186 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
BB Biotech Divests Remaining Stake in Ionis Pharmaceuticals
BB Biotech reported that it fully divested its remaining position in Ionis Pharmaceuticals during the third quarter of 2026.
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
RBC Raises Price Target on Novartis to CHF130
RBC Capital Markets has increased its price target for Novartis AG from CHF120 to CHF130 while maintaining a Sector Perform rating.